Manufacturing

Layoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.
When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
In this episode of Denatured, you’ll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
Neither Chongqing Qiancan Technology nor Tianjin Healthcare Medical Technology provided the records requested by the FDA, leading the agency to issue import alerts and warning letters.
Less than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to support commercial production.
The seven proposals in the Bio Advance plan include easing clinical trial starts, boosting manufacturing and establishing a new White House office to coordinate the government’s biotech policy.
Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
SK pharmteco’s Tatiana Nanda, chief technical officer of SK pharmteco Viral Vector North America discusses what gene therapy sponsors must account for sooner rather than later when preparing for GMP manufacturing.
PRESS RELEASES